Skip to search formSkip to main contentSkip to account menu

idrabiotaparinux

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute… 
Highly Cited
2011
Highly Cited
2011
Summary.  Background: Idraparinux, a long acting inhibitor of factor (F) Xa, is as effective as standard anticoagulant therapy… 
Review
2011
Review
2011
The therapeutic armamentarium of parenteral anticoagulants available to clinicians is mainly composed by unfractionated heparin… 
Highly Cited
2010
Highly Cited
2010
Summary.  Background:  Idraparinux is an inhibitor of activated factor X (FXa) with a long half‐life allowing once‐weekly dosing… 
Review
2010
Review
2010
  • J. Weitz
  • Thrombosis Research
  • 2010
  • Corpus ID: 31157750
2010
2010
  • J. Harenberg
  • Expert Review of Clinical Pharmacology
  • 2010
  • Corpus ID: 207209495
Idraparinux is a polymethylated synthetic pentasaccharide that binds to antithrombin with high affinity. Idrabiotaparinux is a… 
Review
2009
Review
2009
Over the last 15 years, there has been a shift from unfractionated heparin to low-molecular-weight heparin or fondaparinux for… 
Review
2009
Review
2009
  • J. Harenberg
  • Thrombosis and Haemostasis
  • 2009
  • Corpus ID: 10817514
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than… 
Review
2009
Review
2009
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… 
2008
2008
Idrabiotaparinux is a novel synthetic anticoagulant that links idraparinux, a specific, indirect factor Xa inhibitor, to biotin…